Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Eukaryotic Gene Expression
IF: 1.841 5-Year IF: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Print: 1045-4403
ISSN Online: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v20.i2.10
pages 87-103

Tumor Necrosis Factor-α Signaling in Macrophages

Narayanan Parameswaran
Department of Physiology and Division of Pathology, Michigan State University, USA
Sonika Patial
Department of Physiology and Division of Pathology, Michigan State University, USA

ABSTRACT

Tumor necrosis factor-α (TNFα) was cloned over 2 decades ago and its identification in part led to the discovery of a super family of tumor necrosis factors (TNFs) and their receptors. TNFα signals through two transmembrane receptors, TNFR1 and TNFR2, and regulates a number of critical cell functions including cell proliferation, survival, differentiation, and apoptosis. Macrophages are the major producers of TNFα and interestingly are also highly responsive to TNFα. Aberrant TNFα production and TNF receptor signaling have been associated with the pathogenesis of several diseases, including rheumatoid arthritis, Crohn’s disease, atherosclerosis, psoriasis, sepsis, diabetes, and obesity. TNFα has been shown to play a pivotal role in orchestrating the cytokine cascade in many inflammatory diseases and because of this role as a "master-regulator" of inflammatory cytokine production, it has been proposed as a therapeutic target for a number of diseases. Indeed anti-TNFα drugs are now licensed for treating certain inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease. In this review we discuss the discovery of TNFα and its actions especially in regulating macrophage biology. Given its importance in several human diseases, we also briefly discuss the role of anti-TNFα therapeutics in the treatment of inflammatory diseases.


Articles with similar content:

Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Diego Alvarado, Andrew J. Garton, Theresa M. LaVallee, Gerald McMahon, E. Sergio Trombetta, Richard Gedrich
Non-Major Histocompatibility Complex Rheumatoid Arthritis Susceptibility Genes
Critical Reviews™ in Immunology, Vol.31, 2011, issue 2
Saleh M. Ibrahim, Manfred Kunz
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Benjamin Bonavida
Tumor-Stromal Interactions in Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1 - 2
Daniel D. Von Hoff, Richard G. Posner, Haiyong Han, Clifford Whatcott
The Goldilocks Conundrum: NLR Inflammasome Modulation of Gastrointestinal Inflammation during Inflammatory Bowel Disease
Critical Reviews™ in Immunology, Vol.36, 2016, issue 4
Veronica M. Ringel-Scaia, Irving C. Allen, Dylan K. McDaniel